VivoSeq
Infectious Disease

Bacterial Vaginosis

50

Pipeline Programs↗

6

Active Trials↗

18

Companies Involved↗

Bacterial Vaginosis is a moderately active landscape with 50 programs across 18 companies. The most active players are BioNTech, Eli Lilly, Symbiomix Therapeutics. 17 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

82/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BioNTech logo

BioNTech

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1S

Symbiomix Therapeutics

1 program

Phase 2G

Graceway Pharmaceuticals, LLC

1 program

Phase 2S

Salix

1 program

Phase 2T

Toltec Pharmaceuticals, LLC

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Clindamycin-2-Phosphate

Skaraborg Hospital

Oral Metronidazole

Douglas Kwon

Arilin

Clinical Research Center Kiel GmbH

Metronidazole Control

Indiana University School of Medicine

Vaginal Acidifying Gel (rephresh)

Indiana University School of Medicine

Phase 16

Antibiotic

Pfizer

Metronidazole/ Miconazole

Wayne State University

Cervicovaginal Secretions

Johns Hopkins University

Vaginal Capsules of Lactobacilli

The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

Lcfa-01

Massachusetts General Hospital

Phase 210

Rifaximin

Salix

HUDC_VT

Haudongchun Co., Ltd.

LACTIN-V

University of California, San Francisco

Goldencare

CDA Research Group, Inc.

SYM-1219

Symbiomix Therapeutics

Phase 312

Tinidazole

Mission Pharmacal

Lactoferrin

Università degli Studi di Ferrara

Tetracycline and Amphotericin B

Zodiac Produtos Farmaceuticos S.A.

Clindamycin and Ketoconazole

Zodiac Produtos Farmaceuticos S.A.

Gynevac

Amvac Kft.

Approved17

Nystatin

Good Molecules, LLC

Clindamycin

Pfizer

Dexamethasone

Aspen Global Incorporated

Metronidazole

DePuy Orthopaedics

Amoxicillin

Global Antibiotics Research and Development Partnership

Analysis

Trial Status

76

clinical trials

Completed47 · 62%
Unknown status13 · 17%
Terminated8 · 11%
Recruiting5 · 7%
Withdrawn2 · 3%
Active, not recruiting1 · 1%

Clinical Trials

Trial Activity

76 trials

A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis
Recruiting·PPeking University Shenzhen Hospital·Phase 4·NCT04771728·140 enrolled
Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis
Recruiting·HHadassah Medical Organization·N/A·NCT04517487·100 enrolled
Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age
Recruiting·II.M. Sechenov First Moscow State Medical University·Phase 4·NCT06458543·100 enrolled
A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LCFA-01, an Intravaginal Product, in Healthy Participants for Bacterial Vaginosis Treatment
Recruiting·MMassachusetts General Hospital·Phase 1·NCT07514416·30 enrolled
Vaginal Microbiota Transplant to Promote Lactobacillus-dominant Cervicovaginal Communities
Recruiting·—·Preclinical·NCT04046900·62 enrolled
Vaginal Flora for Treatment of Bacterial Vaginosis
Active, not recruiting·HHadassah Medical Organization·N/A·NCT02236429·10 enrolled
Inflammation and Treatment of Bacterial Vaginosis Near Term
Completed·MMedical University of South Carolina·N/A·NCT00720291·59 enrolled
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT01293643·99 enrolled
Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
Completed·SStarpharma Pty Ltd·Phase 2·NCT01201057·132 enrolled
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
Completed·SStarpharma Pty Ltd·Phase 3·NCT01577238·250 enrolled
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Completed·SStarpharma Pty Ltd·Phase 3·NCT02236156·637 enrolled
The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis
Completed·LLondon School of Hygiene and Tropical Medicine·Phase 4·NCT02905890·250 enrolled
Treatment of Bacterial Vaginosis
Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT00324818·600 enrolled
Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue
Completed·CCONRAD·N/A·NCT01347632·35 enrolled
Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology
Completed·UUniversity of Toronto·Phase 1·NCT02527941·50 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)